Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin

Cancer Letters(2021)10.1016/j.canlet.2021.09.020Source: DataRank Database

Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin is a research paper published in Cancer Letters (2021). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.74)OA: greenTopics (54)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Matthew Utter ORCID,María A. Frías ORCID,David A. Foster ORCID,Sohag Chakraborty

Live enrichment

PubMed:34563639 PMC:PMC8513164 OpenAlex:https://openalex.org/W3199661592

National Institutes of Health

Grant: R01-CA046677

National Institutes of Health

Grant: R01-CA179542

NCI NIH HHS

Grant: R01 CA179542

NCI NIH HHS

Grant: R01 CA046677

FWCI

0.74

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8513164

publisherhttps://api.elsevier.com/content/article/PII:S0304383521004675?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383521004675?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2021.09.020

Fields of Study

PI3K/AKT/mTOR signaling in cancerCancer-related Molecular PathwaysUbiquitin and proteasome pathwaysApoptosisCell CycleCell Line, TumorCyclin-Dependent Kinase Inhibitor p16Drug Resistance, NeoplasmE2F Transcription FactorsHumansLung NeoplasmsMaleMutationPhosphorylationProstatic NeoplasmsRetinoblastoma ProteinSignal TransductionSirolimusTransforming Growth Factor beta

MeSH Terms

Cell CycleHumansLung NeoplasmsMaleMutationPhosphorylationProstatic NeoplasmsSignal TransductionRetinoblastoma ProteinTransforming Growth Factor betaApoptosisDrug Resistance, NeoplasmCyclin-Dependent Kinase Inhibitor p16SirolimusCell Line, TumorE2F Transcription Factors

Keywords

DU145Cancer researchCDKN2ACell cycleCancer cellPI3K/AKT/mTOR pathwayE2FCytotoxic T cellmTORC1BiologyCancerCell biologySignal transductionGeneticsrbCell cycle progressionMtorTgfβRapamycin Resistance

Sustainable Development Goals

SDG 0: Good health and well-being

Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin

FAIR Checklist

Authors (4)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)